Geneva, January 5, 2026 – The International Generic and Biosimilar Medicines Association (IGBA), which represents global manufacturers of generic and biosimilar medicines, announced today that Jim Keon, President of the Canadian Generic Pharmaceutical Association (CGPA) and Biosimilars Canada, has assumed the role of IGBA Chair for 2026. He succeeds Shinichiro Hirose, Director of International Affairs at the Japan Generic Medicines Association (JGA).

A research report resulting from a collaboration between the University of Maryland and University of Michigan (USA) delivers a critical set of recommendations emphasizing the urgent need for policies that foster single global development of off patent medicines.

On 20 November, the CEO Advisory Committee of the International Generic and Biosimilar Medicines Association (IGBA) convened to discuss how the generics and biosimilars sector can continue to deliver on its mission—ensuring affordable, safe, effective and quality-assured therapies for patients— in a shifting international landscape.